Human umbilical cord mesenchymal stem cells ameliorate erectile dysfunction in rats with diabetes mellitus through the attenuation of ferroptosis

Huan Feng1, Qi Liu2, Zhiyao Deng1,3, Hao Li1, Huajie Zhang2, Jingyu Song1, Xiaming Liu1, Jihong Liu1, Bo Wen2* and Tao Wang1,3*

Abstract

Background: Erectile dysfunction (ED), as one of the most prevalent consequences in male diabetic patients, has a serious impact on men’s physical and mental health, and the treatment effect of diabetic mellitus erectile dysfunction (DMED) is often worse. Therefore, the development of a novel therapeutic approach is urgent. As stem cells with high differentiation potential, human umbilical cord mesenchymal stem cells (HUCMSCs) have been widely used in the treatment of diseases in other systems, and are expected to be a promising strategy for the treatment of DMED. In this study, we investigated the role of HUCMSCs in managing erectile function in rat models of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) and compared the effects of two different injection methods.

Methods: T1DM and T2DM ED rats were given labelled HUCMSCs by corpus cavernosum injection and tail vein injection, respectively. ICP and MAP were monitored simultaneously by electrical stimulation four weeks after injection to indicate the erectile function of rats. To track the development and colonisation capabilities of stem cells, we performed EdU assay with penile tissue. The histological changes of the penis were observed by hematoxylin–eosin staining, and Masson’s trichrome staining was conducted to evaluate the smooth muscle content and the degree of fibrosis in the rat penis. Then, we employed specific kits to measure the level of NO, cGMP, MDA, SOD and Fe in penis. Electron transmission microscopy was implemented to observe morphology of mitochondria. Besides, western blot and immunofluorescence staining were performed to demonstrate the expression of ferroptosis-related genes.

Results: We found that HUCMSCs improved erectile function in T1DM and T2DM ED rats, with no difference in efficacy between corpus cavernosum injection and tail vein injection. The EdU assay revealed that only a tiny percentage of HUCMSCs colonised the corpus cavernosum, while smooth muscle in the penis expanded and collagen decreased following HUCMSC injection. Moreover, the levels of oxidative stress in the penis of the rats given HUCMSCs were dramatically reduced, as was the tissue iron content. HUCMSCs normalised mitochondrial morphology within corpus cavernosum smooth muscle cells (CCSMCs), which were characteristically altered by high glucose. Furthermore, the...
Introduction

Erectile dysfunction (ED) is one of the most common male sexual dysfunction diseases, with 150 million men suffering from varied degrees of ED around the world [1]. As one of the major complications in men with diabetes mellitus (DM), the incidence of ED in diabetic patients is up to 75% [2]. Men with DM tend to suffer from ED about 10 years earlier than the general population [3]. By 2045, it is estimated that there will be approximately 700 million individuals living with diabetes globally [4]. Despite the fact that PDE5i is now widely acknowledged as a first-line treatment for ED, up to 35% of patients do not react to it [5], which might be owing to diabetes and the consequent severe neurological or vascular lesions. As a result, a more effective therapy for diabetes mellitus erectile dysfunction (DMED) is required.

Mesenchymal stem cells are generated from human bone marrow, umbilical cord tissue, adipose tissue, lung tissue, tooth pulp, and placenta and have immune control, regeneration, and pluripotent differentiation capabilities [6, 7]. Multiple studies have proven that mesenchymal stem cells may be utilised to treat corticosteroid-resistant graft-versus-host disease, multiple sclerosis, osteoarthritis, heart failure, and other indications without substantial adverse effects [8–11].

Human umbilical cord mesenchymal stem cells (HUCMSCs) have a number of benefits over stem cells generated from other organs. To begin with, the collection of HUCMSCs is non-invasive, which reduces the risk of infection significantly. HUCMSCs, on the other hand, have a greater proliferation capacity and can sustain steady growth after the tenth passage, suggesting that they might theoretically have better therapeutic effectiveness at the same dosage [12]. Second, due to their distinct gene expression profile, HUCMSCs are barely tumorigenic and have a higher differentiation capability and self-renewal potential [13, 14]. Low expression of major histocompatibility complex (MHC) class I molecules, a significant absence of MHC class II molecules, and a lack of co-stimulatory ligands such as CD40, CD80, and CD86 further reduced the immunogenicity of HUCMSCs [15]. As a result, it’s clear that HUCMSCs might be an excellent therapy option.

Some clinical trials have indicated that HUCMSCs can safely and effectively treat lung damage and improve decreased lung function in patients with COVID-19 in recent years [16, 17]. HUCMSCs also improved in situ healing capabilities in rhesus monkeys with severe uterine adhesions and decreased mortality in rats with ARDS accompanied by sepsis, according to two other preclinical investigations [18, 19].

Ferroptosis, first proposed by Dixon et al. in 2012 [20], was identified as a non-apoptotic programmed death pathway that relies on iron ions and reactive oxygen species (ROS). Ferroptosis is distinctly different from apoptosis, necrosis, pyroptosis, and autophagy, and is characterised by iron accumulation [21] and overproduction of lipid peroxides [22]. Meanwhile, the characteristic morphological changes of mitochondria in ferroptotic cells can be observed under transmission electron microscope (TEM) [23]. Abundant evidence indicates ferroptosis is involved in various neurodegenerative diseases, and abnormal accumulation of iron in brain tissue will induce massive ROS production in brain cells [24–26]. Liu et al. demonstrated that puerarin prevented pressure overload-induced heart failure by attenuating ferroptosis [27]. In addition, ferroptosis also plays an important role in hepatocellular carcinoma [28–31], colorectal cancer [32], melanoma [33] and becomes a promising therapeutic target of anti-cancer drugs. However, whether ferroptosis is involved in the progression of DMED remains unknown.

Based on these findings, we created animal models of T1DM and T2DM ED rats, with the goal of determining the possible therapeutic benefits of HUCMSCs on DMED and investigating the underlying processes.

Materials and methods

Cell identification and culture
HUCMSCs were donated by Shandong Qilu Cell Therapy Technology Co., Ltd and cultivated at 37 °C in a 5% CO₂ incubator. The fourth passage HUCMSCs were identified by flow cytometry. Flow cytometry was used to identify the HUCMSCs in the fourth passage. For surface
marker verification, the following antibodies were used: CD29, CD31, CD34, CD45, CD90, and CD105 (BD Biosciences, USA).

The multilineage differentiation potential of HUCMSCs was examined using third passage cells, as previously described. For 14 days, cells were grown in adipogenic medium (DME containing 10% FBS, 2 mM dexamethasone, 2 mg/L insulin, 0.5 mM 3-isobutyl-1-methylxanthine, 0.2 mM indomethacin) and for 28 days in osteogenic medium (DME containing 10% FBS, 2 mM dexamethasone, 1 M sodium glycerol phosphate, 10 mM vitamin C). The capacity to develop into adipocytes and osteoblasts was then assessed using Oil red O and Alizarin red S staining.

Our team's typical approach involved isolating corpus cavernosum smooth muscle cells (CCSMCs) from rat penis and purifying them using a differential adhesion method over the course of two weeks [34]. The CCSMCs were then grown in DME with 10% FBS added. CCSMCs were detected by immunofluorescence using antibodies against α-smooth muscle actin (α-SMA; 1:200; Affinity Biosciences, AF1032, USA) and desmin (1:200; Affinity Biosciences, AF5334, USA).

The co-culture system was constructed by a polycarbonate membrane of Costar Transwell Inserts (Corning, No. 3412, USA). The upper and lower chambers were seeded with CCSMCs and HUCMSCs, respectively. The ratio of CCSMCs to HUCMSCs was 1:1.

**Experiments with animals**

Thirty 7-week-old male Sprague–Dawley (SD) rats and thirty 7-week-old male Zucker Diabetic Fatty (ZDF) rats were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd., and they were all fed adaptively for 7 days after fasting overnight. For type 1 diabetes mellitus (T1DM), streptozotocin (STZ; 60 mg/kg; Sigma-Aldrich) was diluted in citrate phosphate buffer (50 mM; pH 4.5) and injected intraperitoneally into SD rats. The rest 6 SD rats were only administrated with the citrate phosphate buffer and placed in the control group. The blood glucose levels of all SD rats were measured three and seven days later, and rats with fasting blood glucose > 16.7 mmol/L at both tests were classified as T1DM. Purina 5008 was given to ZDF rats for 4 weeks to induce type 2 diabetic mellitus (T2DM). The remaining seven rats were designated as the control group and continued to be fed with standard chow. The blood glucose levels of ZDF rats were tested three- and seven-days following induction feeding, and animals with fasting blood glucose levels > 16.7 mmol/L at both assessments were defined as T2DM.

Ten weeks later, all of DM rats survived. Following that, an apomorphine (APO) test was performed to identify the rats with DMED, and those with a negative erection were classified as DMED rats, as in the prior study [35]. Through the APO test, 18 rats each were diagnosed with T1DM and T2DM ED. SD rats were further separated into four groups (DMED group, n = 5; DMED + corpus cavernosum injection (CI) group, n = 7; DMED + tail vein injection (VI) group, n = 6; control group, n = 6). Meanwhile, ZDF rats were separated into four groups (DMED group, n = 5; DMED + corpus cavernosum injection (CI) group, n = 7; DMED + tail vein injection (VI) group, n = 6; control group, n = 7). Two of the groups (the DMED + CI group and DMED + VI group) received HUCMSC injections at different sites and the injection dose was 1 * 10^6 HUCMSCs per rat (injection volume 50 μL), whereas the DMED group and the control group received same volume of saline treatment. Moreover, HUCMSCs were labelled with 5-ethyl-2'-deoxyuridine (EdU; Beyotime, China) according to the manufacturer’s instructions.

**Erectile function evaluation**

The intracavernous pressure (ICP) was monitored four weeks following injection, as previously described [36]. Ketamine (100 mg/kg) and midazolam (5 mg/kg) were used to anaesthetize rats. To measure ICP, a 25-gauge needle was placed into the left penile crus. With micro scissors, a V-shaped incision was created in the carotid artery, a PE-50 tube was inserted, and it was ligated and fastened. The PE tube was pre-filled with heparinised saline (200 IU/mL) and attached to a signal collection device (AD Instruments, Australia), allowing for continuous monitoring of mean arterial pressure (MAP). After that, bipolar electrodes were used to electrically activate the cavernous nerve (15.0 Hz; 5.0 V; for 1 min). The ratio of maximum ICP (max ICP) to MAP (max ICP/MAP) was used to determine erectile function. The rats were slaughtered after their erectile function was assessed, and the penises were dissected from the original tissue. For histologic research, one third of the penis was preserved in paraffin, while the rest were kept at -80 °C for other experiments.

**Immunohistochemistry, hematoxylin–eosin (H&E) staining, and Masson’s trichrome staining**

Immunohistochemistry was performed as previously reported [37]. After antigen retrieval and dewaxed, sections of corpus cavernosum were incubated with antibodies against endothelial nitric oxide synthase (eNOS; 1:100; Affinity Biosciences, AF0096, USA) or neuronal nitric oxide synthase (nNOS; 1:100; Affinity Biosciences, AF6249, USA) antibodies, followed by biotinylated secondary antibodies.
The tissues were fixed for 24 h in 4% paraformaldehyde (Servicebio, China) before being imbedded in paraffin. Serial 4 μm paraffin-embedded slices were obtained and dewaxed in xylene I and xylene II for 10 min each, before being rehydrated in a variety of ethanol concentrations (100% for 5 min, 100% for 5 min, 95% 5 min, 90% 5 min, 80% 5 min, 70% 5 min). The slices were then washed three times in distilled water (5 min each). Finally, according to the manufacturer’s instructions, sections were stained with H&E solution (Servicebio, China).

Masson’s trichrome staining was conducted according to the standard protocol. The area of smooth muscle and collagen was determined with ImageJ software. The ratio of smooth muscle to collagen was taken as an indicator of the degree of fibrosis in the corpus cavernosum.

Fluorescence staining
A superoxide anion fluorescent probe (Dihydroethidium, DHE; Yeasen Biotechnology) and the Reactive Oxygen Species Assay Kit (2,7-Dichlorodihydrofluorescein diacetate, DCFH-DA; Yeasen Biotechnology) were used to measure the quantity of ROS in the corpus cavernosum. DHE and DCFH-DA were used to incubate tissue and cell sections, respectively.

As previously stated, penis samples were preprocessed. GPX4 (1:200; ABclonal, A1933, China) and ACSL4 (1:200; ABclonal, A1933, China) were used to incubate sections (1:200; Affinity Biosciences, DF12141, USA). The slides were then treated with the appropriate secondary antibodies before being stained with 4', 6-diamidino-2-phenylindole (DAPI, Invitrogen) for nuclear staining.

Sections were assessed for EdU labelling using the BeyoClick™ EdU Assay Kit with Alexa Fluor 647 (Beyotime, China), for 30 min at room temperature. The above sections were inspected under a fluorescence microscope.

Measurement of oxidative activity
The levels of malondialdehyde (MDA) and superoxide dismutase (SOD) reflected the oxidative and antioxidant activities, respectively. The Micro MDA Assay Kit (Solarbio, BC0025, China) and SOD assay kit (Nanjing Jiancheng Bioengineering Institute, A001-3-2, China) were used to detect these two indicators according to the manufacturer’s instructions.

Assessment of iron content
The content of Fe in corpus cavernosum was evaluated by Tissue Iron Assay Kit (Nanjing Jiancheng Bioengineering Institute, A039-2-1, China) according to the manufacturer’s instructions.

Examination of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) levels
Nitrate-nitrite Assay Kit (Beyotime, S0024, China) was used to detect the level of NO, and the cGMP levels were determined ELISA kit (R&D Systems, F15182, USA) according to the standard protocol. The results were normalised to the protein concentration.

Transmission electron microscope analysis
Cells were fixed with Electron Microscope Fixative Solution (Servicebio, G1102, China) for 1 h, then were re-fixed with 1% osmic acid in 0.1 M phosphate buffered saline (pH 7.4) at room temperature for 2 h. Next, adding 50%, 70%, 80%, 90%, 95%, 100% and 100% ethanol to dehydrate in sequence, 15 min each time. Finally, they were embedded in SPI-Pon 812 (SPI, 0529–77–4, USA). An ultramicrotome (UC, Leica) was used to cut 60 nm ultrathin sections, which were stained with 2% uranyl acetate and lead citrate, subsequently. Sections were examined under a Hitachi electron microscope (Hitachi, HT7800, Japan).

Western blotting
Proteins were extracted by RIPA lysis buffer (Boster, AR0102, China) supplemented with 1% PMSF (Boster, AR1178, China), 1% protease inhibitor (Boster, AR1182, China) and 1% protease inhibitor cocktail (MCE, HY-K0010, China). SDS-PAGE was used to separate the proteins, which were then transferred to PVDF membranes. After blocking with Tris-buffered saline-Tween with 5% bovine serum albumin for 1 h at room temperature, membranes were incubated with primary antibodies against SLC7A11 (1:500; ABclonal, A13685, China), GPX4 (1:500; ABclonal, A1933, China), ACSL4(1:1000; Affinity Biosciences, DF12141, USA), LPCAT3 (1:500; ABclonal, A17604, China), ALOX15 (1:500; ABclonal, A6864, China) and β-Actin (1:200,000; ABclonal, AC026, China) at 4 °C overnight. Then, the membranes were hybridised with goat anti-rabbit secondary antibody (1:10,000; Boster, BA1055, China) and visualised by ChemiDoc Touch Imaging System (Bio-Rad, USA).

Reagent
RSL3 is one of ferroptosis agonists. CCSMCs were exposed to 500 nmol/L RSL3 (MCE, HY-100218A, China) for 24 h in order to induce ferroptosis. Ferroptosis inhibitor ferrostatin-1 (Fer-1; 1 μmol/L; MCE, HY-100579, China) was added to medium to inhibit ferroptosis in CCSMCs.
Statistical analysis
The IHC were quantified by Image-Pro Plus 6.0 software, and results were analysed with GraphPad Prism 8.3. Statistical analyses were conducted using one-way ANOVA followed by the Tukey’s test for post hoc comparisons. \( P < 0.05 \) was defined as statistically significant.

Results
Characterisation of HUCMSCs and CCSMCs
The isolated stem cells showed typical fibroblast morphology when they were passed to the third passage (Fig. 1A). To identify HUCMSCs, we used flow cytometry to detect the expression of specific markers. As shown in the Fig. 1B, most cells expressed CD29, CD90, and CD105, although CD31, CD34, and CD45 were seldom

**Fig. 1** Primary culture and characterisation of HUCMSCs. **A** Morphological features of HUCMSCs at third passage. The magnification is \( \times \) 100. **B** Representative flow cytometry histograms of HUCMSCs. **C** Adipogenic differentiation of HUCMSCs assessed by Oil Red O staining. The magnification is \( \times \) 200. **D** Osteogenic differentiation of HUCMSCs assessed by Alizarin Red S staining. The magnification is \( \times \) 200. **E** Representative immunofluorescence results of CCSMCs show positive expression for \( \alpha \)-SMA and desmin. The magnification is \( \times \) 100. HUCMSCs human umbilical cord mesenchymal stem cells, CCSMCs corpus cavernosum smooth muscle cells, \( \alpha \)-SMA \( \alpha \)-smooth muscle actin, DAPI 4',6-diamidino-2-phenylindole.
expressed. Meanwhile, with the multipotency of HUCMSCs, we successfully induced them into adipocytes and osteoblasts, which indicated by Oil red O staining and Alizarin red S staining, respectively (Fig. 1C, D).

CCSMCs were isolated from rat penis, as in our prior investigation [34]. The cells were then identified by immunofluorescence staining (Fig. 1E), which revealed that they exhibited significant levels of α-SMA and desmin, suggesting that the cells we extracted and cultivated were CCSMCs.

**Metabolic indices**

As illustrated in Fig. 2, there was no significant difference in the initial body weight and fasting blood glucose among all groups, whether T1DM or T2DM rats. In T1DM rats, the DMED group, CI group, and VI group had higher blood glucose and lower body weight than the control group ten weeks after induction, but in T2DM rats, the DMED group, CI group, and VI group had higher blood glucose and body weight than the control group. These findings consistently demonstrated that we had successfully created a rat model of T1DM and T2DM.

**HUCMSCs could improve erectile function in DMED rats**

The ratio of max ICP to MAP reflected erectile function. In T1DM rats (Fig. 3A, C), the indicator was dramatically reduced in the DMED group and significantly improved following injection of HUCMSCs into the corpus cavernosum or tail vein. It also revealed a consistent trend in T2DM rats at the same period (Fig. 3B, D).

**HUCMSCs suppressed penile histological changes in vivo**

We detected the colonisation of stem cells by EdU assay (Additional file 1: Fig. S1), however only very low fluorescence intensity was seen in the penile tissue of type 1 and type 2 DMED rats following stem cell injection. The corpus cavernosum smooth muscle atrophy was discovered in the diabetic group (Fig. 4B). The smooth muscle regeneration and reduction in cavernous fibrosis, on the other hand, occurred in the CI and VI groups, and the smooth muscle/collagen ratio rose considerably in both groups (Fig. 4C, D). Importantly, following HUCMSC injection, there was no substantial alteration in the anatomy of the rat penis, no inflammation, no tissue necrosis, and no tumour growth in the corpus cavernosum (Fig. 4A).
HUCMSCs retained NO activity in vivo

We employed particular kits to quantify NO and cGMP concentrations in rat penises, same as we did in our previous work [38]. NO and cGMP production in the penis of DMED rats were severely suppressed, although they were somewhat enhanced after stem cell injection, according to the findings (Additional file 2: Fig. S2A–D). We next used immunohistochemistry to examine the quantity of eNOS and nNOS in the rat penis, two enzymes that mediated the synthesis of NO in the corpus cavernosum for erection maintenance. The levels of eNOS and nNOS in the DMED group were found to be lower than those in the control group, whereas they were somewhat higher in the CI and VI groups (Additional file 2: Fig. S2E, F).

HUCMSCs reduced iron content and inhibited oxidative stress in vivo

To explore and confirm the role of ferroptosis in DMED, we examined the iron content and oxidative stress in rat penis. The results revealed that the iron content in DMED rats’ penis was much higher, but the iron content of rats in the CI and VI groups was significantly lower, which was observed in both T1DM and T2DM rats (Fig. 5A, B). MDA levels exhibited a similar trend as a sign of oxidative stress, and HUCMSCs obviously reduced MDA concentration in DMED rats (Fig. 5C, D). In contrast, SOD acted as an antioxidant in the body and exhibited the exact opposite changes to MDA (Fig. 5E, F). Then, DHE staining was conducted in the corpus cavernosum to reflect ROS (Fig. 6). The results showed...
that ROS expression was higher in the DMED group, and HUCMSCs attenuated ROS production significantly in the CI and VI groups.

**HUCMSCs decreased oxidative stress in vitro**

In order to confirm the inhibitory effect of HUCMSCs on oxidative stress in vitro. We cultivated HUCMSCs and...
CCSMCs in the co-culture system (Fig. 7A). The amount of ROS was measured by DCFH-DA staining (Fig. 7B, C). The findings demonstrated that smooth muscle cells produced more ROS than usual in a high-glucose environment and after RSL3 treatment, and that the quantity of ROS dropped dramatically after co-culture with HUCMSCs, but CCSMCs exposed to the ferroptosis inhibitor Fer-1 showed a consistent trend.

**HUCMSCs attenuated ferroptosis through SLC7A11/GPX4/ACSL4 pathway in vitro**

Mitochondria in ferroptotic cells exhibited specific morphological changes. We observed the shrunken mitochondria, decreased or complete absence of mitochondria cristae and high electron density in RSL3-treated CCSMCs by electron microscopy. Meanwhile, CCSMCs treated with high glucose displayed comparable alterations, suggesting that diabetes might cause ferroptosis in CCSMCs. However, after co-culturing with HUCMSCs, the morphological changes in mitochondria were significantly improved, and normal mitochondrial structure could be observed (Fig. 7D).

As an important component of the cystine transporter system Xc−, SLC7A11-mediated cystine uptake plays a vital role in inhibiting cellular oxidative stress. In Fig. 8, the expression of SLC7A11 in CCSMCs treated with high glucose and RSL3 was significantly lower than in normal cells, according to Western blot analysis, and HUCMSCs had a clear ability to rescue its expression, which was consistent with CCSMCs treated with Fer-1. GPX4 is one of the most well-known ferroptosis defence pathways, and its expression in each group followed the same pattern as SLC7A11. While ACSL4, LPCAT3, and ALOX15, which promote oxidative stress during ferroptosis, were clearly elevated in CCSMCs treated with high glucose, they were significantly reduced after co-culture with HUCMSCs.

**Discussion**

It’s been reported that the global incidence of erectile dysfunction is expected to rise to 322 million cases by 2025 [1, 39, 40]. Diabetes is a major risk factor for erectile dysfunction, and peripheral neuropathy, atherosclerosis of large vessels, endothelial dysfunction of small arteries and hypogonadism can eventually lead to erectile dysfunction [41–44]. We investigated the effect of HUCMSCs on DMED rats’ erectile function through corpus cavernosum injection and tail vein injection, respectively,
based on the construction of T1DM and T2DM ED rats. The impaired erectile function of DMED rats was significantly improved without side effects, and the underlying molecular mechanism by which HUCMSCs could attenuate ferroptosis in CCSMCs was confirmed, all of which indicated that HUCMSCs could be a promising emerging therapeutic strategy for DMED.

HUCMSCs, a kind of naïve stem cell found in the human body, may be collected in great quantities without posing a risk to the donor, and the application of HUCMSCs does not raise ethical problems. In recent years, some studies have revealed that bone mesenchymal stem cells (BMSCs) and adipose-derived stem cells (ADSCs) could improve the erectile function of DMED to some extent [45, 46], similar to how HUCMSCs have been shown to have good therapeutic effects on diseases of the immune system, cardiovascular system, and digestive system [47–49]. The real therapeutic benefits of BMSCs and ADSCs to DMED, however, are restricted due to their high degree of differentiation and low biological stability [50–54]. Furthermore, certain clinical trials have showed that PDE5i is still necessary to sustain erection following

**Fig. 6** Effects of HUCMSCs on reducing ROS production in vivo. Representative immunofluorescence (× 200) (A) and quantification (B) of ROS in the corpus cavernosum of T1DM rats. Representative immunofluorescence (× 200) (C) and quantification (D) of ROS in the corpus cavernosum of T2DM rats. Data are expressed as means ± standard deviation. *P < 0.05 versus the control group; #P < 0.05 versus the DMED group. ROS reactive oxygen species, IOD integrated option density, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, Con control, DMED diabetes mellitus erectile dysfunction, CI corpus cavernosum injection, VI tail vein injection, DAPI 4',6-diamidino-2-phenylindole
the administration of BMSCs or ADSCs [55, 56]. T1DM and T2DM rats given HUCMSCs had considerable improvement in their erectile function, and there were no evident rejection or other adverse effects following injection, demonstrating the biological safety of HUCMSCs. The favourable impact of stem cells in tissue repair, according to Matz et al., is more dependent on paracrine activity, the production of cytokines and growth factors that reduce inflammation and promote healing, than on colonisation and differentiation [57]. We labelled the cells with EdU before injecting them to investigate the exact mechanism of HUCMSCs in the treatment of DMED [58–60]. It revealed that only a small number of labelled HUCMSCs colonised the rat penis. Since HUCMSCs are human-derived cells, it is difficult for HUCMSCs to directly differentiate into various cell types in the rat penis to repair tissues, which might be the reason why we observed only a small number of stem cell colonisation.
Päth et al. also disclosed that, despite not having successfully differentiated into β cells, mesenchymal stem cells (MSCs) can secrete a variety of immunomodulatory and tissue regeneration factors to lower blood glucose levels [61]. In several clinical trials, researchers discovered that MSCs reduced and delayed the destruction of β cells in many T1DM patients, but did not restore their function [62–64]. And the anti-inflammatory properties of MSCs were exploited to treat chronic low-grade inflammation in T2DM patients, which was thought to be a major cause of insulin resistance and β-cell dysfunction [65]. Based on the above, we speculated that HUCMSCs might primarily repair tissue via paracrine. Interestingly, we noticed that there was a slight improvement in hyperglycemia in...
T2DM ED rats after injection, but not in T1DM ED rats, even though HUCMSCs did not restore fasting glucose to normal in both types of DMED rats. Based on these, we preliminarily confirmed that HUCMSCs ameliorated ED through a glucose independent manner. On the other hand, more severe hyperglycemia might exacerbate irreversible damage to pancreatic cells, vascular smooth muscle cells, vascular endothelial cells, and cavernous nerves in T1DM rats.

Stem cell treatment for ED was previously administered mostly through the corpus cavernosum, abdominal cavity, and tail vein. There was only one study comparing the efficacy of corpus cavernosum and tail vein injection of ADSCs in rats with nerve-injured ED [66]. In fact, DMED is currently more common than nerve-injured ED. Our findings are the first to compare the therapeutic effects of HUCMSCs on two types of DMED rats by CI and VI. The therapeutic effects of the two methods are almost identical, and there are no obvious differences in various indicators. It was demonstrated that HUCMSCs could effectively improve the erectile function of rats through CI and VI. This could serve as a starting point for future research on HUCMSCs as a DMED treatment.

As revealed by Masson's trichrome staining, we found that the ability of HUCMSCs to suppress cavernous fibrosis might contribute to their therapeutic impact in ED. One of the key causes of DMED, as revealed in a previous study [67, 68], is corpus cavernosum fibrosis, which is induced by reduced corpus cavernosum smooth muscle and increased collagen. In both types of DMED rats, we noticed a considerable loss in smooth muscle and a significant rise in collagen, but these histological alterations were greatly relieved following stem cell therapy, indicating that HUCMSCs had a good anti-fibrotic activity.

NO causes the corpus cavernosum smooth muscle to relax by promoting the synthesis of cGMP in CCSMCs, which is produced by eNOS in cavernous endothelial cells and nNOS in cavernous neurons. Our data argued that HUCMSCs might increase the abundance of eNOS and nNOS in the corpus cavernosum of DMED rats, boosting NO and cGMP levels, implying that HUCMSCs could alleviate DMED via the NO/cGMP pathway.

Ferroptosis plays a crucial role in the occurrence and progression of various diseases, and regulating the ferroptosis pathway presents a potential therapeutic strategy for many diseases [69–71]. The intracellular antioxidant system, System Xc−, is made up of two subunits, SLC7A11 and SLC3A2. Through the System Xc−, cysteine and glutamic acid collaborate to synthesize glutathione, and glutathione then lowers ROS and reactive nitrogen via glutathione peroxidase (GPX). Inhibition of System Xc− function interferes with GSH production, resulting in reduced GPX activity, decreased cellular antioxidant capacity, lipid ROS buildup, and, ultimately, oxidative damage and ferroptosis [72]. GPX4, member of the GPX family, is a critical regulator of ferroptosis via limiting the formation of lipid peroxides. GPX4 converts glutathione to oxidised glutathione peptide (GSSG), and reduce cytotoxic lipid peroxidation to the corresponding alcohol. Inhibition of GPX4 activity leads to accumulation of lipid peroxides, a hallmark of ferroptosis [73]. However, the role of ferroptosis in ED remains unclear. First, we found that HUCMSCs diminished iron content and oxidative stress levels in DMED rats’ penis, including MDA, SOD, and ROS. Second, HUCMSCs were able to enhance the abundance of SLC7A11 and GPX4 while decreasing the expression of lipid metabolism-related genes such ACSL4, LPCAT3, and ALOX15. Furthermore, intracellular mitochondria treated with high glucose showed morphological abnormalities that were rescued by HUCMSCs. Those proved that HUCMSCs might alleviate DMED by prohibiting the ferroptosis signalling pathway in CCSMCs.

There are some limitations in current study. We utilised the DMED rat model to explore the impact of HUCMSCs on DMED and the underlying mechanism, however additional study is needed to better understand its safety, effectiveness, and other unknown concerns before it can be used in clinical practise. In the following investigation, we’ll build rabbit, dog, and possibly monkey animal models to further confirm the therapeutic efficacy of HUCMSCs on DMED. Second, the injection dose used in the study was one million cells, which is consistent with other studies [50, 51, 74–76]. It is unclear whether there is an ideal dose yet, therefore we will compare outcomes from different doses in future studies to find the optimal injection dose. Finally, HUCMSCs secrete cytokines [77], chemokines [78], growth factors [79], proteases [80], and extracellular vesicles [81] to exert paracrine effects, but we have not yet figured out which paracrine mode of HUCMSCs mediate to suppress ferroptosis in CCSMCs. We will conduct appropriate in vivo and in vitro experiments to explore the specific paracrine mode of HUCMSCs repairing CCSMCs, so as to further clarify the mechanism of HUCMSCs in the treatment of DMED.

**Conclusions**

In summary, the current investigation found that HUCMSCs improved erectile function in T1DM and T2DM ED rats without major adverse events. Moreover, it was uncovered that HUCMSCs not only inhibited corpus cavernosum fibrosis and activated NOS, but prevented diabetes-induced ferroptosis in CCSMCs. Furthermore, we found that HUCMSCs possessed equal efficacy in the therapy of DMED when injected into the corpus...
cavernous and tail vein. These findings provide pre-clinical evidence for a potential treatment for DMED and new insights into the therapeutic mechanism of HUCMSCs in the treatment of DMED.

Abbreviations
ED: Erectile dysfunction; DMED: Diabetic mellitus erectile dysfunction; HUCMSCs: Human umbilical cord mesenchymal stem cells; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; CSMCs: Corpus cavernosum smooth muscle cells; DM: Diabetes mellitus; MHC: Major histocompatibility complex; DAPI: 4',6-Diamidino-2-phenylindole; eNOS: Endothelial nitric oxide synthase; nNOS: Neuronal nitric oxide synthase; cGMP: Cyclic guanosine monophosphate; NO: Nitric oxide; TEM: Transmission electron microscope; BMSCs: Bone mesenchymal stem cells; ADSCs: Adipose-derived stem cells; MSCs: Mesenchymal stem cells; GPX: Glutathione peroxidase; GSSG: Glutathione peptide.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13287-022-03147-w.

Additional file 1: Fig. S1. Examination of colonization of HUCMSCS. Representative immunofluorescence (× 200) (A) of EdU in the corpus cavernosum of T1DM rats after HUCMSCS injection. Representative immunofluorescence (× 200) (B) of EdU in the corpus cavernosum of T2DM rats after HUCMSCS injection. C) corpus cavernosum injection, V) tail vein injection, EdU) 5-Ethynyl-2'-deoxyuridine; ICP: Intracavernous pressure; MAP: Mean arterial pressure; H&E: Hematoxylin–eosin; eNOS: Endothelial nitric oxide synthase; nNOS: Neuronal nitric oxide synthase; DAPI: 4',6-Diamidino-2-phenylindole; MDA: Malondialdehyde; SOD: Superoxide dismutase, cGMP: Cyclic guanosine monophosphate; NO: Nitric oxide; TEM: Transmission electron microscope; BMSCs: Bone mesenchymal stem cells; ADSCs: Adipose-derived stem cells; MSCs: Mesenchymal stem cells; GPX: Glutathione peroxidase; GSSG: Glutathione peptide.

Additional file 2: Fig. S2. Assessment of NO and cGMP. The levels of NO in the corpus cavernosum of T1DM (A) and T2DM (B) rats. The cGMP concentration in the corpus cavernosum of T1DM (C) and T2DM (D) rats. Representative results of immunohistochemistry analysis of nNOS (E) and eNOS (F) in the corpus cavernosum of rats. The magnification is × 200. The arrows indicate nNOS and eNOS expression (Because the expression levels of nNOS and eNOS in DMED group were very low, the coloring was very light). (G) The relative expression of nNOS and eNOS in the corpus cavernosum of T1DM and T2DM rats. Data are expressed as means ± standard deviation. *P < 0.05 versus the control group; #P < 0.05 versus the DMED group. cGMP cyclic guanosine monophosphate; NO nitric oxide, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, Con control, DMED diabetes mellitus erectile dysfunction, CI corpus cavernosum injection, V) tail vein injection, eNOS endothelial nitric oxide synthase, nNOS neuronal nitric oxide synthase

Acknowledgements
We would like to thank Shandong Qilu Cell Therapy Technology Co, Ltd for its help.

Author contributions
WT and HF contributed to the conception. HF, ZD, HL and JS performed the whole experimental work. HF, QL and HZ contributed to data acquisition and analysis. HF and XL drafted the work. TW, BW, and JL supervised the work. All authors read and approved the final manuscript.

Funding
This work was supported by the Natural Science Foundation of Shenzhen [JCYJ20210324134400002, JCYJ20210324141404010] and Hubei Provincial Medical Youth Top Talent Project.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
The animal study was reviewed and approved by Experimental Animal Administration Committee of Wuhan Servicebio Biotechnology.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interest exists.

Author details
1 Department of Urology, Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. 2 Department of Urology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, Guangdong, China. 3 Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, Guangdong, China.

Received: 30 March 2022 Accepted: 18 August 2022
Published online: 05 September 2022

References
1. Burnett AL, Nehra A, Breau RH, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633–41.
2. Koudad Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34:1185–92.
3. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163:460–3.
4. Tonnies T, Rathmann W, Hoyer A, Brinks R, Kuss O. Quantifying the underestimation of projected global diabetes prevalence: the International Diabetes Federation (IDF) diabetes Atlas. BMJ Open Diabetes Res Care. 2021;9:e002122.
5. Shamliol R, Ghanem H. Erectile dysfunction. Lancet. 2013;381:153–65.
6. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824–33.
7. Behrke J, Kremmer S, Shahzad T, Chaom B, Böttcher-Friebertshäuser E, Morty RE, et al. MSC based therapies-new perspectives for the injured lung. J Clin Med. 2020;9:682.
8. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwingjiga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol. 2013;163:501–9.
9. Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017;13:391–405.
10. Pas HI, Winters M, Haisma HJ, Koenis MJ, Tol JL, Moen MH. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2017;51:1125–33.
11. Guo R, Morimatsu M, Feng T, Lan F, Chang D, Wan F, et al. Stem cell-derived cell sheet transplantation for heart tissue repair in myocardial infarction. Stem Cell Res Ther. 2020;11:19.
12. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoietic-supportive function and other potentials. Haematologica. 2006;91:1017–26.
13. Fong CY, Chak LL, Biswas A, Tan JH, Gautamahan K, Chan WK, et al. Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev Rep. 2011;7:1–16.
14. Hishej YF, Fu YS, Chang SJ, Tsuang YH, Wang HW. Functional module analysis reveals differential osteogenic and stemness potentials in human mesenchymal stem cells from bone marrow and Wharton’s jelly of umbilical cord. Stem Cells Dev. 2010;19:1895–910.
15. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, et al. Immunogenicity of umbilical cord tissue derived cells. Blood. 2008;111:430–8.

16. Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5:172.

17. Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6:38.

18. Wang L, Yu C, Chang T, Zhang M, Song S, Xiong C, et al. In situ repair abilities of human umbilical cord-derived mesenchymal stem cells and autologously transplanted hyaluronic acid gel complex in rheus monkeys with intrauterine adenoma. Sci Adv. 2020;6ea6357.

19. Lee FY, Chen KH, Wallace CG, Sung PH, Sheu JJ, Chung SY, et al. Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis. Oncotarget. 2017;8:45626–42.

20. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.

21. Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. BHQ-cyanine-based “off-on” long-circulating assembly as a ferroptosis amplifier for cancer treatment: a lipid-peroxidation burst device. ACS Appl Mater Interfaces. 2019;11:42873–84.

22. Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019;9:2009–23.

23. Miyake S, Murai S, Kakuta S, Uchiyama Y, Nakano H. Identification of the hallmark of necroptosis and ferroptosis by transmission electron microscopy. Biochem Biophys Res Commun. 2020;527:839–44.

24. Lane D, Ayton S, Bush AI. Iron and Alzheimer’s disease: an update on emerging mechanisms. J Alzheimers Dis. 2018;64:S379–95.

25. Yuan P, Ma D, Gao X, Wang J, Li R, Liu Z, et al. Liraglutide ameliorates erectile dysfunction by inhibiting fibrosis and modulating the NO/cGMP pathway. J Cell Mol Med. 2020;24:13289–302.

26. Luan Y, Cui K, Tang Z, Ruan Y, Liu K, Wang T, et al. Human tissue collagen 1 improves erectile function of streptozotocin-induced diabetic rats by inhibition of excessive oxidative stress and activation of the PI3K/AKT/eNOS pathway. Oxid Med Cell Longev. 2020;2020:6834236.

27. Bacon CG, Mittelmann MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med. 2003;139:161–8.

28. Ayta IA, McInlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50–6.

29. Yaf FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.

30. Corona G, Giorda CB, Cucinotta D, Guida P, Nada E. The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J Endocrinol Invest. 2013;36:864–8.

31. Corona G, Giorda CB, Cucinotta D, Guida P, Nada E. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med. 2014;11:2065–73.

32. Corona G, Rastrelli G, Balerica G, Lotti F, Erozka A, Monami M, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J Sex Med. 2012;9:1669–80.

33. He X, Yang Y, Yao M, Yang L, Ao L, Xu K, et al. Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with ß-NGF treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:1298–304.

34. Kim HS, Shin TH, Lee BC, Yu KR, Seo Y, Lee S, et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology. 2013;145:1902–10.

35. Bartolucci J, Verdufo DJ, Gonzalez PL, Larrea RE, Abaruza E, Gose G, et al. Safety and efficacy of the intravenously infused of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;121:1192–204.

36. Liu G, Sun X, Ruan J, Wu R, Guan X, Ouyang B, et al. Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS ONE. 2013;8:e72790.

37. Jeon SH, Zhu QG, Bae WJ, Choi SW, Jeong HC, Cho HJ, et al. Engineered mesenchymal stem cells expressing stromal cell-derived factor-1 improve erectile dysfunction in streptozotocin-induced diabetic rats. Int J Mol Sci. 2018;19:E3730.

38. Das ND, Song KM, Yin GN, Batnold D, Kwon MH, Kwon KD, et al. Xenogenic transplantation of human breast adipose-derived stromal vascular fraction enhances recovery of erectile function in diabetic mice. Biop Reprod. 2014;90:66.

39. Wang X, Liu C, Xu Y, Chen P, Shen Y, Xu Y, et al. Combination of mesenchymal stem cell injection with icariin for the treatment of diabetes-associated erectile dysfunction. PLoS ONE. 2017;12:e71445.

40. Yang Q, Chen W, Zhang C, Xie Y, Gao Y, Deng C, et al. Combined transplantation of adipose tissue-derived stem cells and endothelial progenitor cells improves diabetic erectile dysfunction in a rat model. Stem Cells Int. 2020;2020:2154053.

41. Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins F, et al. Stem Cell Research & Therapy          (2022) 13:450
56. Matz EL, Terlecki RP. Stem cell and gene-based therapy for erectile dysfunction: current status and future needs. Urol Clin North Am. 2021;48:611–9.

57. Matz EL, Terlecki R, Zhang Y, Jackson, J, Atala A. Stem cell therapy for erectile dysfunction. Sex Med Rev. 2019;7:321–8.

58. Lin CS, Xin ZC, Wang Z, Deng C, Huang YC, Lin G, et al. Stem cell therapy for erectile dysfunction: a critical review. Stem Cells Dev. 2012;21:343–51.

59. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A. 2008;105:2415–20.

60. Fandel TM, Albersen M, Lin G, Qiu X, Ning H, Banier L, et al. Recruitment of intracavernously injected adipose-derived stem cells to the major pelvic ganglion improves erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012;61:201–10.

61. Path G, Perakakis N, Mantzoros CS, Seufert J. Stem cells in the treatment of diabetes mellitus: focus on mesenchymal stem cells. Metabolism. 2019;90:1–15.

62. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48:2221–8.

63. Carlsson PO, Schwarz E, Korsgren O, Le Blanc K. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64:587–92.

64. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60:347–57.

65. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.

66. Chen X, Yang Q, Xie Y, Deng C, Liu G, Zhang X. Comparative study of different transplantation methods of adipose tissue-derived stem cells in the treatment of erectile dysfunction caused by cavernous nerve injury. Andrologia. 2021;53:e13950.

67. Ruan Y, Li M, Wang T, Yang J, Rao K, Wang S, et al. Taurine supplementation improves erectile function in rats with streptozotocin-induced type 1 diabetes via amelioration of penile fibrosis and endothelial dysfunction. J Sex Med. 2016;13:778–85.

68. Liu K, Cui K, Feng H, Li R, Lin H, Chen Y, et al. JTE-013 supplementation improves erectile dysfunction in rats with streptozotocin-induced type diabetes through the inhibition of the rho-kinase pathway, fibrosis, and apoptosis. Andrology. 2020;8:497–508.

69. Fang X, Cai Z, Wang H, Han D, Cheng Q, Zhang P, et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. Circ Res. 2020;127:486–501.

70. Weiland A, Wang Y, Wu W, Lan X, Han X, Li Q, et al. Ferroptosis and its role in diverse brain diseases. Mol Neurobiol. 2019;56:4880–93.

71. Belavagi A, Meyer C, Stumpf J, Hugo C, Linkermann A. Ferroptosis and necroptosis in the kidney. Cell Chem Biol. 2020;27:448–62.

72. Stockwell BR, Friedmann AJ, Bays H, Bush AE, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273–85.

73. Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.

74. Chen S, Zhu J, Wang M, Huang Y, Qiu Z, Li J, et al. Comparison of the therapeutic effects of adipose- and bone marrow mesenchymal stem cells on erectile dysfunction in diabetic rats. Int J Mol Med. 2019;44:1006–14.

75. Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med. 2010;7:89–98.

76. Kovanecz I, Vernet D, Masouminia M, Gelfand R, Loni L, Aboagye J, et al. Implanted muscle-derived stem cells ameliorate erectile dysfunction in a rat model of type 2 diabetes, but their repair capacity is impaired by their prior exposure to the diabetic milieu. J Sex Med. 2016;13:786–97.

77. Li JY, Ren KK, Zhang WJ, Xiao L, Wu HY, Liu QY, et al. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway. Stem Cell Res Ther. 2019;10:247.

78. Praveen Kumar L, Kandoi S, Misra R, Vijayalakshmi S, Rajagopal K, Verma RS. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1–9.

79. Baer PC, Geiger H. Mesenchymal stem cell interactions with growth factors on kidney repair. Curr Opin Nephrol Hypertens. 2010;19:1–6.

80. Li H, Rong P, Ma X, Nie W, Chen Y, Zhang J, et al. Mouse umbilical cord mesenchymal stem cell paracrine alleviates renal fibrosis in diabetic nephropathy by reducing myofibroblast transdifferentiation and cell proliferation and upregulating mmps in mesangial cells. J Diabetes Res. 2020;2020:3847171.

81. Sun Y, Shi H, Yin S, Ji C, Zhang X, Zhang B, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction. ACS Nano. 2018;12:7613–28.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.